PatientFocus

patientfocus.com

PatientFocus is a medical billing company, that functions as an outsourced extension of our clients’ billing office. We focus exclusively on patient-pay billing – after insurance (or no insurance) and before bad debt – and facilitate patient communications, payment management, and patient financing options. The heart of the PatientFocus solution is the patient. Our unique combination of people, process and platform, and our “Day One” approach results in a highly coordinated, more comprehensive, and extremely efficient outreach program that protects both the patients’ experience and our clients’ brand.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

news image

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More

INDUSTRIAL IMPACT

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

news image

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More

AGC BIOLOGICS TO PARTICIPATE IN FIRST-EVER BIO DIGITAL CONFERENCE

AGC Biologics | May 14, 2020

news image

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....

Read More

CELL AND GENE THERAPY

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

news image

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More
news image

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More
news image

INDUSTRIAL IMPACT

PROVIDENCE THERAPEUTICS SIGNS LICENSING AGREEMENT WITH SICKKIDS FOR IMMUNOTARGETING TECHNOLOGY

Providence Therapeutics | July 13, 2022

Providence Therapeutics, Canada's premier mRNA medicines company, is pleased to announce that it has entered into an exclusive licensing agreement with The Hospital for Sick Children of Toronto, ON, for an immunotargeting technology platform. This platform provides an innovative approach to generating adjuvant-free vaccines and works by targeting Antigen Presenting Cells of the immune system via the MHC Class II molecules on their surface. This can result in an enhanced immune response to an...

Read More
news image

AGC BIOLOGICS TO PARTICIPATE IN FIRST-EVER BIO DIGITAL CONFERENCE

AGC Biologics | May 14, 2020

AGC Biologics, a global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), will be participating in the first-ever BIO Digital event. BIO International Conference is holding its annual event virtually this year in order to safely connect industry experts amidst the COVID-19 global pandemic. The event, which takes place June 8 - 12, brings together capital, scientific and development expertise that is required to turn promising innovation into successful medicine....

Read More
news image

CELL AND GENE THERAPY

NEW STUDY HIGHLIGHTS CELL AVIDITY'S POWER TO PROVIDE INSIGHTS INTO THE ROBUSTNESS OF T CELL ACTIVATION

LUMICKS | March 24, 2022

LUMICKS, a next generation life science tools company, today announced that a research study published in Cellular and Molecular Life Sciences from the Radboud University Medical Center, led by researchers in the team of Professor G. J. Adema, detailed a novel method to study lead compound effects on immune cell interactions by employing LUMICKS' z-Movi® Cell Avidity Analyzer. The interaction between dendritic cells (DCs) and T cells is a critical step in the activation of...

Read More